NEKTAR Therapeutics
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 54-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis
Volunteers needed for up to a 59 week long clinical trial with up to 19 office visits for an investigational product. $1,200.00 stipend available. Additional compensation will be available for participants who are travelling extensive distance to participate (with prior approval).
To Qualify, you must meet the following INCLUSION CRITERIA:
1.) 18+ years of age (max age of 70 years)
2.) Have MODERATE to SEVERE eczema (atopic dermatitis)
3.) Minimum of 10% eczema affected body surface area to be determined by Investigator at Screening Visit.
To Qualify, you must NOT meet the following EXCLUSION CRITERIA:
1.) Prior use of biological medications or JAK inhibitors for treatment of Atopic Dermatitis
2.) Unwilling to discontinue current atopic dermatitis treatments
3.) Female who is pregnant or breastfeeding
ClinicalTrials.gov Identifier: NCT NCT06136741
https://clinicaltrials.gov/study/NCT06136741?term=nektar&rank=6
Nektar Therapeutics Logo
We love our patients, so feel free to visit during normal business hours.
510 S Cowley Spokane, WA 99202
Mon | 09:00 am – 05:00 pm | |
Tue | 09:00 am – 05:00 pm | |
Wed | 09:00 am – 05:00 pm | |
Thu | 09:00 am – 05:00 pm | |
Fri | 09:00 am – 05:00 pm | |
Sat | Closed | |
Sun | Closed |
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.